Genetic and antigenic analysis of Bordetella pertussis isolates recovered from clinical cases in Ontario, Canada, before and after the introduction of the acellular pertussis vaccine

Canadian Journal of Microbiology

Volumn 51, Issue 10, 2005, Pages 887-892

  Tsang, Raymond S W ^a   Sill, Michelle L ^a   Martin, Irene E ^a   Jamieson, Frances ^b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

Author keywords

Acellular vaccine; Genetic analysis; Pertussis

Indexed keywords

DNA; ELECTROPHORESIS; TOXIC MATERIALS; VACCINES;

ACELLULAR VACCINE; GENETIC ANALYSIS; PERTUSSIS;

GENETIC ENGINEERING;

ACELLULAR VACCINE; FIMBRIA PROTEIN; PENTACEL; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; QUADRACEL;

GENETIC VARIATION;

ARTICLE; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; CANADA; DNA SEQUENCE; DRUG EFFICACY; GENETIC ANALYSIS; GENETIC VARIABILITY; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SEROTYPING;

ANTIGENIC VARIATION; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; ELECTROPHORESIS, GEL, PULSED-FIELD; FIMBRIAE PROTEINS; HUMANS; ONTARIO; PERTUSSIS TOXIN; PERTUSSIS VACCINE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SEROTYPING; VACCINES, ACELLULAR; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

CANADA; NORTH AMERICA; ONTARIO;

BACTERIA (MICROORGANISMS); BORDETELLA PERTUSSIS;

EID: 32544450825     PISSN: 00084166     EISSN: None     Source Type: Journal    
DOI: 10.1139/w05-079     Document Type: Article

References (18)

1. Andrews, R., Herceq, A., and Roberts, C. 1997. Pertussis notification in Australia, 1991-1997. Commun. Dis. Intell. 21: 145-148.
2. Bass, J.W., and Stephenson, S.R. 1987. The return of pertussis. Pediatr. Infect. Dis. J. 6: 141-144.
3. Bass, J.W., and Whittler, R.R. 1994. Return of pertussis epidemic in the United States. Pediatr. Infect. Dis. J. 13: 343-345.
4. Boursaux-Eude, C., Thiberge, S., Carletti, G., and Guiso, N. 1999. Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine. Vaccine, 17: 2651-2660.
5. Cassiday, P., Sanden, G., Heuvelman, K., Mooi, E, Bisgard, M., and Popovic. T. 2000. Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J. Infect. Dis. 182: 1402-1408.
6. De Serres, G., Shadmani, R., Duval, B., Boulianne, N., Dery, P., Douville Fradet, M., and Halperin, S.A. 2000. Morbidity of pertussis in adolescent and adults. J. Infect. Dis. 182: 174-179.
7. Fry, N.K., Neal, S., Harrison, T.G., Miller, E., Matthews, R., and George, R.C. 2001. Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect. Immun. 69: 5520-5528.
8. Gautom, R. 1997. Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other Gram-negative organisms in 1 day. J. Clin. Microbiol. 35: 2977-2980.
9. Gzyl, A., Augustynowicz, E., van Loo, I., and Slusarczyk, J. 2001. Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine, 20: 299-303.
10. Gzyl, A., Augustynowicz, E., Gniadek, G., Rabczenko, D., Dulny, G., and Slusarczyk, J. 2004. Sequence variation in pertussis SI subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Vaccine, 22: 2122-2128.
11. Hardwick, T.H., Cassiday, P., Weyant, R.S., Bisgard, K.M., and Sanden, G.N. 2002. Changes in predominance and diversity of genomic subtypes of Bordetella pertussis isolated in the United States, 1935 to 1999. Emerg. Infect. Dis. 8: 44-49.
12. Hausman, S.Z., and Burns, D.L. 2000. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization. Infect. Immun. 68: 3763-3767.
13. Mooi, F.R., van Oirschot, H., Heuvelman, K., van der Heide, H.G., Gaastra, W., and Willems, R.J. 1998. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect. Immun. 66: 670-675.
14. Mooi, F.R., He, Q., van Oirschot, H., and Mertsola, J. 1999. Variations in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect. Immun. 67: 3133-3134.
15. Peppler, M.S., Kuny, S., Nevesinjac, A., Rogers, C., de Moissac, Y.R., Knowles, K., Lorange, M., De Serres, G., and Talbot, J. 2003. Strain variation among Bordetella pertussis isolates from Quebec and Alberta provinces in Canada from 1985 to 1994. J. Clin. Microbiol. 41: 3344-3347.
16. Senzilet, L.D., Halperin, S.A., Spika, J.S., Alagaratnam, M., Morris, A., Smith, B., and The Sentinel Health Unit Surveillance System Pertussis Working Group. 2001. Pertussis is a frequent cause of prolonged cough illness in adolescent and adults. Clin. Infect. Dis. 32: 1691-1697.
17. Tsang, R.S.W., Lau, A.K.H., Sill, M.L., Halperin, S.A., Van Caeseele, P., Jamieson, F., and Martin, I.E. 2004. Polymorphisms of the fimbriae fim3 gene of Bordetella pertussis strains isolated in Canada. J. Clin. Microbiol. 42: 5364-5367.
18. Van Loo, I.H.M., Heuvelman, K.J., King, A.J., and Mooi, F.R. 2002. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J. Clin. Microbiol. 40: 1994-2001.